Candel Therapeutics, Inc.

Candel Therapeutics is a clinical-stage biopharmaceutical company that develops off-the-shelf viral immunotherapies designed to stimulate systemic immune responses against cancer. Its investigational pipeline features two primary clinical candidates: aglatimagene besadenovec, an adenovirus-based therapy evaluated for localized prostate cancer, non-small cell lung cancer, and pancreatic cancer, and linoserpaturev, a herpes simplex virus construct being evaluated for recurrent high-grade glioma. The company also engineers early-stage solid tumor candidates using its enLIGHTEN discovery platform. Its target patients include individuals with solid tumors, especially those showing limited responses to standard oncology treatments.

Operationally, the company conducts multi-center clinical studies in the United States and Mexico. It retains development and commercialization rights across major territories, including the United States, Europe, and Asia, while utilizing third-party contract manufacturers for production. The business is incorporated in Delaware; its specific headquarters location is not stated in the text.

Summary of the business section of Candel Therapeutics's latest annual report, written by StockData.

“As of December 31, 2025, we had 55 employees.”